PMID- 31303779
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220409
IS  - 1178-7023 (Print)
IS  - 1178-7023 (Electronic)
IS  - 1178-7023 (Linking)
VI  - 12
DP  - 2019
TI  - Clinicopathological features and Borrmann classification associated with 
      HER2-positive in primary gastric cancer.
PG  - 287-294
LID - 10.2147/CEG.S212895 [doi]
AB  - PURPOSE: Human epidermal growth factor receptor 2 (HER2) assesment is important 
      for patients with advanced gastric cancer (GC) to determine trastuzumab therapy 
      is being considered. A study was performed to evaluate the rate of HER2 
      positivity in patients with primary gastric cancer and to assess the relationship 
      between HER2-positive and Borrmann classification. PATIENTS AND METHODS: Four 
      hundred and sixty-one patients with gastric or gastroesophageal junction cancer 
      were confirmed as having adenocarcinoma between 2005 and 2016. HER2 status was 
      assessed using immunohistochemistry (IHC) and/or fluorescence in situ 
      hybridization (FISH). Tissues were considered to be HER2-positive when assessment 
      revealed either an IHC score of 3+ or IHC score 2+ accompanied by a positive FISH 
      result. RESULTS: The HER2-positive rate was significantly higher in men than in 
      women (19% vs 9%; p=0.006). In our study, HER2-positive gastric tumors with 
      differentiated histology were significantly higher. The proportion of 
      HER2-positive gastric tumors of Borrmann classification III or IV was 
      significantly higher than tumors classified as I or II. CONCLUSIONS: 
      HER2-positive gastric cancer tends to be associated with male gender, 
      differentiated histology, and Borrmann tumor classification of III or IV.
FAU - Dai, Xiaomin
AU  - Dai X
AD  - Department of Pathology, Zhejiang Hospital, Hangzhou, Zhejiang, People's Republic 
      of China.
FAU - Zhang, Xijiong
AU  - Zhang X
AD  - Department of Pathology, The No.1 People's Hospital of Pinghu, Jiaxing, Zhejiang, 
      People's Republic of China.
FAU - Yu, Jin
AU  - Yu J
AD  - Department of Pathology, Zhejiang Hospital, Hangzhou, Zhejiang, People's Republic 
      of China.
AD  - Department of Pathology, The No.1 People's Hospital of Pinghu, Jiaxing, Zhejiang, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20190628
PL  - New Zealand
TA  - Clin Exp Gastroenterol
JT  - Clinical and experimental gastroenterology
JID - 101532800
PMC - PMC6605773
OTO - NOTNLM
OT  - Borrmann classification
OT  - FISH
OT  - HER2 gastric cancer
OT  - immunohistochemistry
COIS- The authors have declared that no competing interests exist in this work.
EDAT- 2019/07/16 06:00
MHDA- 2019/07/16 06:01
PMCR- 2019/06/28
CRDT- 2019/07/16 06:00
PHST- 2019/04/19 00:00 [received]
PHST- 2019/05/27 00:00 [accepted]
PHST- 2019/07/16 06:00 [entrez]
PHST- 2019/07/16 06:00 [pubmed]
PHST- 2019/07/16 06:01 [medline]
PHST- 2019/06/28 00:00 [pmc-release]
AID - 212895 [pii]
AID - 10.2147/CEG.S212895 [doi]
PST - epublish
SO  - Clin Exp Gastroenterol. 2019 Jun 28;12:287-294. doi: 10.2147/CEG.S212895. 
      eCollection 2019.